NO20001238L - Monoklonalt antistoff som induserer apoptose - Google Patents

Monoklonalt antistoff som induserer apoptose

Info

Publication number
NO20001238L
NO20001238L NO20001238A NO20001238A NO20001238L NO 20001238 L NO20001238 L NO 20001238L NO 20001238 A NO20001238 A NO 20001238A NO 20001238 A NO20001238 A NO 20001238A NO 20001238 L NO20001238 L NO 20001238L
Authority
NO
Norway
Prior art keywords
antibody
monoclonal antibody
associated proteins
human integrin
apoptosis
Prior art date
Application number
NO20001238A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001238D0 (no
Inventor
Naoshi Fukushima
Shinsuke Uno
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20001238D0 publication Critical patent/NO20001238D0/no
Publication of NO20001238L publication Critical patent/NO20001238L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20001238A 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose NO20001238L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26485397 1997-09-11
PCT/JP1998/004118 WO1999012973A1 (fr) 1997-09-11 1998-09-11 Anticorps monoclonal induisant l'apoptose

Publications (2)

Publication Number Publication Date
NO20001238D0 NO20001238D0 (no) 2000-03-09
NO20001238L true NO20001238L (no) 2000-05-11

Family

ID=17409137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001238A NO20001238L (no) 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose

Country Status (14)

Country Link
US (1) US20030157100A1 (sk)
EP (1) EP1035132B1 (sk)
KR (2) KR20010023866A (sk)
CN (1) CN1198845C (sk)
AT (1) ATE395362T1 (sk)
AU (1) AU740225B2 (sk)
CA (1) CA2303072A1 (sk)
DE (1) DE69839492D1 (sk)
HU (1) HUP0003513A3 (sk)
NO (1) NO20001238L (sk)
PL (1) PL339265A1 (sk)
RU (1) RU2212413C2 (sk)
SK (1) SK3232000A3 (sk)
WO (1) WO1999012973A1 (sk)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE280835T1 (de) * 1993-09-03 2004-11-15 Chugai Pharmaceutical Co Ltd Apoptose induzierender monoklonaler antikörper
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
EP1167388A4 (en) * 1999-03-10 2002-05-29 Chugai Pharmaceutical Co Ltd APOPTOSE INDUCING SINGLE STRING FV
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
TWI241345B (en) * 2000-03-10 2005-10-11 Chugai Pharmaceutical Co Ltd Apoptosis inducing polypeptide
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
WO2001079494A1 (fr) * 2000-04-17 2001-10-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistes
WO2002033073A1 (fr) * 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agoniste degrade
DE60133479T2 (de) 2000-10-20 2009-04-16 Chugai Seiyaku K.K. Modifizierter tpo-agonisten antikörper
CN1308447C (zh) * 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
AU2002210917B2 (en) * 2000-10-20 2006-05-18 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
ATE414105T1 (de) 2002-10-11 2008-11-15 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
EP1609803A4 (en) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODY AGAINST CD22 AND ITS USE
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
WO2005044857A1 (ja) * 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha ヒト化抗cd47抗体
AU2004297109A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
EP1927367A4 (en) * 2005-05-18 2009-08-12 Univ Tokushima NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US20070113297A1 (en) * 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
AR061986A1 (es) * 2006-07-13 2008-08-10 Chugai Pharmaceutical Co Ltd Agentes inductores de muerte celular
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2740823T3 (es) 2008-01-15 2020-02-06 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
EP2340034B2 (en) 2008-08-07 2019-02-13 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Radioprotectants targeting thrombospondin-1 and cd47
PL2812443T3 (pl) * 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
NZ740686A (en) 2015-09-18 2021-12-24 Arch Oncology Inc Therapeutic cd47 antibodies
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
MX2020005463A (es) 2017-12-01 2020-09-07 Seattle Genetics Inc Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
CA3234825A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods of generating cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
ATE280835T1 (de) * 1993-09-03 2004-11-15 Chugai Pharmaceutical Co Ltd Apoptose induzierender monoklonaler antikörper
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
AU2232597A (en) * 1996-03-06 1997-09-22 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis

Also Published As

Publication number Publication date
PL339265A1 (en) 2000-12-04
KR20010023866A (ko) 2001-03-26
EP1035132B1 (en) 2008-05-14
CN1276798A (zh) 2000-12-13
HUP0003513A2 (hu) 2001-02-28
WO1999012973A1 (fr) 1999-03-18
EP1035132A4 (en) 2005-02-09
CN1198845C (zh) 2005-04-27
HUP0003513A3 (en) 2004-05-28
AU9002898A (en) 1999-03-29
DE69839492D1 (de) 2008-06-26
SK3232000A3 (en) 2000-09-12
ATE395362T1 (de) 2008-05-15
KR20040106585A (ko) 2004-12-17
RU2212413C2 (ru) 2003-09-20
US20030157100A1 (en) 2003-08-21
AU740225B2 (en) 2001-11-01
EP1035132A1 (en) 2000-09-13
NO20001238D0 (no) 2000-03-09
CA2303072A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
NO20001238L (no) Monoklonalt antistoff som induserer apoptose
FI960567A (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
CY1117114T1 (el) Εξανθρωπισμενα ανοσορρυθμιστικα μονοκλωνικα αντισωματα για την θεραπευτικη αγωγη νεοπλασματικης ασθενειας ή ανοσοανεπαρκειας
ATE123652T1 (de) Antigene.
PT921395E (pt) Ensaio para medicao de fragmentos de proteina em meios biologicos
DE69228701D1 (de) Fragmente von Prion Proteinen.
FI955798A0 (fi) Terapeuttiset vasta-ainefrangmentit
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ES2133738T3 (es) Metodo para cuantificar lbp en fluidos corporales.
AU9648301A (en) Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor
DE3872754T2 (de) Nachweis von antikoerpern humaner immundefizienz-viren.
EP0444856A3 (en) Diagnostic assay for alzheimer's disease
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DE3854553T2 (de) Verfahren zum schnellen und empfindlichen Nachweis von IgM-Antikörpern gegen retrovirale Antigene.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
FI973484A (fi) Menetelmä immuunivasteen stimuloimiseksi
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
BR9903250A (pt) Antìgenos e imunoanálises para diagnóstico da doença de chagas.
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
PT744027E (pt) Utilizacao de metodos para identificar oligopeptidos de sinal hidrofilicos
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
ES2099678B1 (es) Procedimiento para la inactivacion de virus en proteinas.